Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non-small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and phosphoinositide-3 kinase (PI3K) pathways for acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC. We investigated the efficacy of combined trametinib plus taselisib therapy using experimentally established EGFR-TKI-resistant NSCLC cell lines. The results showed that the feedback loop between MEK/ERK and PI3K/AKT pathways had developed in several resistant cell lines, which caused the resistance to single-agent treatment with either inhibitor alone. Meanwhile, the combined therapy successfully regulated the compensatory activation of the key intracellular signals and synergistically inhibited the cell growth of those cells in vitro and in vivo. The resistance mechanisms for which the dual kinase inhibitor therapy proved effective included (MET) mesenchymalepithelial transition factor amplification, induction of epithelial-to-mesenchymal transition (EMT) and EGFR T790M mutation. In further analysis, the combination therapy induced the phosphorylation of p38 MAPK signaling, leading to the activation of apoptosis cascade. Additionally, long-term treatment with the combination therapy induced the conversion from EMT to mesenchymal-to-epithelial transition in the resistant cell line harboring EMT features, restoring the sensitivity to EGFR-TKI. In conclusion, our results indicate that the combined therapy using MEK and PI3K inhibitors is a potent therapeutic strategy for NSCLC with the acquired resistance to EGFR-TKIs.
formation from NSCLC into small cell lung cancer. [3] [4] [5] [6] [7] [8] Recently,
osimertinib, a third-generation EGFR-TKI, was developed to overcome the resistance associated with the EGFR T790M mutation, and is expected to play an important role in the treatment of advanced NSCLC. 9 However, the emergence of resistance to osimertinib by various mechanisms, including the appearance of the EGFR C797S mutation, has already become a serious problem. [10] [11] [12] These phenomena demand the development of novel therapeutic strategies for advanced NSCLC with acquired resistance to EGFRTKIs.
In attempting to overcome acquired resistance to EGFR-TKIs caused by "receptor tyrosine kinase (RTK)-targeted" therapy, the downstream pathways could be viewed as reasonable next targets.
The emergence of the EGFR T790M mutation is known to lead to reactivation of the MEK/ERK or PI3K/AKT pathway. [13] [14] [15] Several studies have also demonstrated that MET amplification promotes resistance to TKIs by reactivating both the PI3K/AKT and MEK/ ERK pathways. 4, 16 Thus, most of the resistance mechanisms were associated with unexpected aberrant re-awakening of the key intracellular signals that were basically inhibited by the TKIs. However, although these pathways are attractive therapeutic targets, it is well known that the inhibition of one pathway can lead to compensatory activation of the other pathway, which leads to diminished efficacy of single-agent therapies, 17 and overcoming the feedback loop is one of the major issues for molecular targeted therapy in many types of cancer. Among such intrinsic mutual compensation systems of intracellular signal transduction networks in cancer, the tight relationship between MEK/ERK and PI3K/AKT pathways has been of particular interest. [18] [19] [20] [21] 
| MATERIALS AND METHODS

| Cell lines and reagents
We used three human NSCLC cell lines (HCC827, HCC4006, and PC-9), five gefitinib-resistant (GR) cell lines (HCC827-GR-step
[GRS], HCC827-GR-high [GRH], HCC4006-GRS, HCC4006-GRH, and PC-9-GRS), and four afatinib-resistant (AR) cell lines (HCC827-ARS, HCC827-ARH, HCC4006-ARS, and HCC4006-ARH). The characteristics of these resistant cell lines are described in our previous reports and summarized in Table 1 . 7, 8 We used trametinib, which is a potent and selective MEK1/2 inhibitor that was approved by the Food and Drug Administration for the treatment of BRAF V600E-mutant NSCLC in combination with the BRAF inhibitor dabrafenib. 27 For PI3K inhibition, we selected taselisib, which has been shown in early-phase clinical trials to be of clinical benefit for solid tumors harboring PIK3CA alterations. 28 The details about these cell lines, the reagents, and the antibodies for western blot analysis are included in the Data S1.
| Determination of cell proliferation
Cell proliferative ability was determined by a modified 3-(4,5- 
| Combination effect
The combination effect of two drugs was evaluated using the combination index (CI). The CI values were calculated using the Calcusyn software (Biosoft, Cambridge, UK), as previously described. 29 The combination effect is classified as follows: CI < 1: synergistic effect; 
| Detection of apoptotic cells by Hoechst staining and cell cycle analysis
Cells were seeded onto 6-cm dishes and treated with trametinib (100 nmol/L) alone, taselisib (100 nmol/L) alone, or a combination of the two for 48 hours. The nuclear morphology and the cell cycle distribution were assessed as described in Data S1.
| Western blot analysis
The detailed protocol for western blot analysis has been previously described. 7 The relative band intensity was assessed by densitometric analysis using ImageJ (National Institute of Health, Bethesda, MD, USA).
| Human Phospho-MAP Kinase Array
HCC827-GRS and HCC4006-GRS cells were treated with trametinib (100 nmol/L) plus taselisib (100 nmol/L). After 48-hour treatment, the total protein was purified, and the cell lysates were applied to the 
| mRNA and microRNA expression analyses by quantitative reverse-transcription-PCR
The details about cDNA and microRNA (miR) synthesis are described in Data S1 and our previous report 7. The TaqMan assays were purchased from Thermo Fisher Scientific (San Jose, CA, USA), and the catalog numbers are shown in Table S1 .
| Microarray and Gene Set Enrichment Analysis (GSEA)
Purified total RNA samples extracted from the resistant cell lines were hybridized on the Human Whole Genome DNA Microarray system (SurePrint G3 Human 8x60K ver. 3.0, Agilent Technologies, 
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EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; IC 50 , 50% inhibitory concentration; MET, mesenchymal-epithelial transition factor;TKIs, tyrosine kinase inhibitors.
Santa Clara, CA, USA) to analyze the alterations in the gene expression profiles. The specific enrichments of gene sets were further analyzed using the GSEA software (GSEA ver. 2.0).
32,33
| Statistical analyses
All in vitro experiments except for a phospho-MAP Kinase Array were performed at least three times. Data are expressed as the mean ± standard deviation. Statistical analyses were performed using the JMP ® 9.0.0 software for Windows (SAS Institute, Inc., Cary, NC, USA). All statistical tests were two-sided, and probability values <.05
indicated statistically significant differences.
| RESULTS
| Effect of MEK plus PI3K dual inhibition on the cell growth activity in NSCLC cell lines
We first examined the growth-inhibitory effect of trametinib, taselis- and ARS, and PC-9-GRS) against which the dual kinase inhibitor therapy was particularly effective, as compared to the effect of singleagent therapies. The survival curves for these cell lines are shown in Figure 1A , and the effects of the drug combination were evaluated by the CI values. As shown in Figure 1B , a strong synergistic effect of combined trametinib plus taselisib therapy was observed even at low concentrations.
| Combined trametinib plus taselisib therapy suppressed the activation of downstream signaling in EGFR-TKI-resistant NSCLC cell lines
To gain insight into the intracellular signaling events involved in the growth suppression caused by concurrent use of trametinib plus taselisib, we examined the alterations in the expression levels of key protein molecules associated with cancer progression. As shown in Figure S1B ). Based on these results, the alterations of the relative values of the key molecules related to the MAPK cascade were calculated by densitometric analysis. As expected, the phosphorylation of ERK1/2 and AKT was suppressed ( Figure S1C ). In addition, the combined inhibitor therapy induced the phosphorylation of p38α, p38β and p38δ, and their downstream molecule, heat shock protein 27, whereas it had no effect on the phosphorylation level of pan-JNK ( Figure 4C ). In HCC827-GRS and HCC4006-GRS, western blot analysis also revealed that the combined inhibitor therapy induced the PARP cleavage displayed by c-PARP appearance concomitant with the phosphorylation of p38 but not of JNK, to which a pan-p38 inhibitor SB203580 reduced the expression of c-PARP.
On the other hand, this phenomenon was not observed in HCC827-ARS cells that were resistant to the same combined therapy in apoptotic events ( Figure 4D ). These results may indicate that the Figure 4F ). Knowing this, we performed western blot analysis to examine the phosphorylation status of key molecules on the PI3K/AKT/mTOR pathway. As a result, in the apoptosis-sensitive group, all the phosphorylation levels of AKT, mTOR, and S6 showed tendency to be higher than those in the apoptosis-resistant group, which was consistent with the result of GSEA ( Figure S2 ). The activation of PI3K/AKT/mTOR cascade is a renowned pathway to give cancer cells an anti-apoptotic force; therefore, it is reasonable to consider that the tight regulation of the pathway by combined therapy results in higher efficacy in the apoptosis-sensitive group in comparison to the apoptosis-resistant group.
| Effect of combined therapy with trametinib plus taselisib on the EGFR-TKI-resistant NSCLC cell line harboring EMT features
It is well known that TGF-β signaling promotes the acquisition of the | 3191 changes were observed, and on day 7 after discontinuation of the drug exposure, the cell morphologies were restored to those observed before the drug exposure ( Figure 5A ). We subsequently examined the alterations of the EMT-related markers in this setting. In western blot analysis, the HCC827-ARS cells treated with the combination of trametinib plus taselisib for 7 days showed evidence of MET, with upregulation of E-cadherin and downregulation of vimentin and zinc finger Ebox binding homeobox 1 (ZEB)1 ( Figure 5B ). Moreover, after discontinuation of exposure to the drugs, the features of EMT were restored in the HCC827-ARS cells, accompanied by morphological changes of the cells. In addition, 7-day treatment with trametinib plus taselisib restored the expression of miR-200c, which has been implicated in EMT through the reciprocally linked feedback loop with ZEB1 and ZEB2, 34 and on day 7 after discontinuation of exposure to the drugs, the expression of miR-200c returned to its original level ( Figure 5C ).
Meanwhile, the combined inhibitor therapy did not affect the expression of aldehyde dehydrogenase 1 family member A1 (ALDH1A1), which is one of the cancer stem cell markers ( Figure 5D ). We further investigated the change in the sensitivity of HCC827-ARS to afatinib, when the drug was used concurrently with trametinib and taselisib. with other types of MEK and PI3K inhibitors, trametinib and taselisib, have not been clinically examined. Our results suggest that the dual inhibition of MEK plus PI3K pathways using our selected trametinib and taselisib may be helpful with a potent therapeutic strategy for NSCLC with acquired resistance to EGFR-TKI.
One of the major obstacles in single-agent therapies, targeting only one intracellular pathway, is compensatory activation of another intracellular pathway in a negative feedback loop. 17 In our experiment, in 5 out of 9 resistant cell lines, the feedback loop between MEK/ERK and PI3K/AKT pathways had already developed before treatment, causing resistance to single-agent therapy with inhibitors of either pathway.
This result indicates that the compensatory activation between the central oncogenic pathways is one of the important issues that need to be overcome also in NSCLC after TKI failure.
We have pointed out the possibility that the p38 MAPK pathway plays an important role in the activation of apoptosis induced by the MEK plus PI3K dual blockade therapy. The p38 MAPK is a family of stress-activated protein kinases that are usually activated by a variety of extracellular stresses. In human tissues, four isoforms (p38α, p38β, p38γ, and p38δ) have been identified, are expressed ubiquitously at different levels in tissues, and have different functions. 35 Conventionally, the p38 MAPK cascade has been regarded to function as a tumor-suppressive pathway by negatively regulating cell survival and proliferation. 36, 37 In contrast, recent studies have reported that the activation of p38 MAPK pathway also promotes the acquisition of drug resistance, tumor progression, and metastasis in several types of cancers. On the other hand, the dual inhibitor therapy proved to be insufficient/of limited efficacy for three resistant cell lines harboring EMT features; namely, no inhibition of cell growth was observed in the HCC827-GRH cells, and in the HCC827-ARS and HCC4006-ARS cells, while growth inhibition was observed, the resistance to cell apoptosis was implied. Although the detailed mechanism underlying this resistance to the dual MEK plus PI3K inhibition remains unclear, the stem cell properties of the cells may provide some clue. As we have reported previously, a putative stem cell marker, ALDH1A1, was expressed in all three resistant cell lines, 7, 8 although there were obvious differences in the level of expression ( Figure S3) , and the resistant cell lines with higher expression levels of ALDH1A1 also showed a higher resistance level to the combined inhibitor therapy.
These results may imply that not only the appearance of EMT, but also that of stem cell properties may underlie the resistance of the cells to the combined inhibitor therapy. Several studies indicated the involvement of multiple pathways for the acquisition and maintenance of cancer stem cell (CSC) properties. Cordenonsi and colleagues reported that Hippo pathway, which is a conserved regulator of organ size, plays an essential role for acquisition of CSC properties. 45 Takebe and colleagues also mentioned that CSC is characterized by its aberrant activation of various signal transduction pathways, such as the Notch, Hedgehog, and Wnt pathways. 46 Thus, 
